Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-28

Clinical Trial Update: Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the effect of tiotropium inhalation capsules (Spiriva) on exercise tolerance in COPD patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Spiriva (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED